In line with this, one study found that EGFR inhibition in osteosarcoma cell lines, while having only limited cytotoxicity on its own, was able to enhance the antiproliferative and antimigration effects of doxorubicin and methotrexate, suggesting that EGFR targeting may be one way to potentiate treatment with these drugs (see Section 3). The gene discussed is EGFR; the disease is osteosarcoma.